ABBV · AbbVie

The thesis

AbbVie's shares are modestly more likely than not to beat the S&P 500 over the next three months, because Skyrizi and Rinvoq each grew more than 22% in the 30 October 2026 third-quarter report and pushed 2026 guidance higher. The question is settled by the fourth-quarter report, expected around 29 January 2027, which brings AbbVie's first 2027 guidance. That guidance shows whether the growth supports a valuation well above the stock's own history.

The shares closed at $294.45 on 12 November 2026, 2.8% below the 52-week intraday high of $302.93 set on 5 November 2026. They are up 18.8% over three months on adjusted daily closes. Analysts keep raising targets after the report: Argus Research moved to $320 from $270 on 6 November 2026, and Berenberg moved to $305 from $275 on 11 November 2026 and kept its Buy rating, per fiscal.ai.

The price already reflects the growth. TIKR put AbbVie at 19 times forward earnings on 29 October 2026, against a five-year average of 14 times. Further gains depend on the 2027 outlook beating the current outlook, not on the third-quarter numbers that are already known. Company news since 4 November 2026 has been pipeline deals, conference data and awards. None of it changes 2026 drug sales.

Bullish and bearish views on AbbVie Inc.

The bull case on AbbVie Inc. (ABBV), in brief: both growth drugs held above 20%. The bear case: fourth-quarter guidance looks soft.

Bull case

• Both growth drugs held above 20%. Skyrizi revenue was $5.776 billion in Q3 2026, up 22.7%, and Rinvoq was $2.706 billion, up 23.9%, per AbbVie's 30 October 2026 release. Immunology grew 16.3% to $9.165 billion even with Humira down 31.2% to $683 million.
• Guidance and the dividend both rose. On 30 October 2026 AbbVie raised 2026 adjusted earnings per share (EPS) guidance to $13.95–$13.99 from $13.76–$13.96 and revenue guidance to about $67.8 billion from $67.6 billion. Simply Wall St reported that AbbVie also raised its quarterly dividend by 5.2%, starting in February 2027.
• Targets are still rising after the report. Berenberg lifted its target to $305 from $275 on 11 November 2026, and Argus lifted its target to $320 from $270 on 6 November 2026, per fiscal.ai. The 10-Q filed on 3 November 2026 reports quarterly revenue of $17.40 billion, against $15.78 billion a year earlier.
• Neuroscience is a second growth engine. Neuroscience revenue rose 19.4% to $3.389 billion in Q3, per the 30 October 2026 release. On 2 November 2026 AbbVie and Brise Pharmaceuticals disclosed a license for two preclinical migraine programs worth up to $757 million in milestones plus royalties, per BioXconomy.
• Immunology adds an oral candidate. On 4 November 2026 AbbVie took exclusive worldwide rights to Nxera Pharma's NXE0033744, an oral EP4 receptor agonist for inflammatory bowel disease (IBD). Nxera said a completed Phase 1 study supports a gut-selective profile.
• Oncology has readouts on fixed dates. AbbVie filed etentamig for multiple myeloma with the US Food and Drug Administration (FDA) on 27 October 2026. Genmab and AbbVie will present 22 epcoritamab abstracts, including Phase 3 data, at the American Society of Hematology (ASH) meeting, per their 4 November 2026 announcement.

Bear case

• Fourth-quarter guidance looks soft. AbbVie guided Q4 adjusted EPS to $3.83–$3.87 and Q4 revenue to about $18.4 billion on 30 October 2026. MarketBeat named that outlook, which came in under Wall Street's estimate, as a reason for the 3 November 2026 decline.
• The valuation is high against history. TIKR's 19 times forward earnings on 29 October 2026 compares with a five-year average of 14 times. BNP Paribas raised its target only to $269 from $247 on 3 November 2026, per fiscal.ai, which is under the 12 November 2026 close.
• A senior executive sold near the high. Executive Vice President and Chief Commercial Officer Jeffrey Ryan Stewart exercised options on 40,619 shares and sold 40,619 shares at $293.60 on 9 November 2026, per his Form 4 filed 12 November 2026. The exercise and the sale came on the same day.
• Deals keep costing earnings. Nxera gets $100 million upfront and up to $1.37 billion in milestones plus royalties, per the 4 November 2026 announcement. AbbVie expects its Apogee acquisition, completed 3 September 2026, to cut 2027 adjusted EPS by about $0.46.
• Humira and aesthetics hold back growth. Humira fell 31.2% in Q3 2026 under US biosimilar competition, per the 30 October 2026 release. Allergan Aesthetics presented Phase 4 data on patients taking GLP-1 drugs on 8 November 2026, but AbbVie kept its 2026 aesthetics guidance at $5 billion.
• US pricing changes start in January. A 340B rebate model for Imbruvica, Linzess and Vraylar starts on 1 January 2027, and Vraylar's Medicare-negotiated price takes effect the same day. AbbVie has not put a number on the 340B effect.

Price setup

The shares closed at $294.45 on 12 November 2026, after a close of $294.98 on 11 November 2026. They have closed higher than the $288.24 close of 5 November 2026 in each session since. That was the day of the $302.93 intraday 52-week high, so the shares have not returned to that level on a closing basis.

On adjusted daily closes as of 12 November 2026, the 50-day moving average is $273.87 and the 200-day moving average is $237.78. The shares sit about 7.5% above the 50-day average, and the kill line sits just below it. A close under the 50-day average would mean the shares have given back most of their gain since the third-quarter report. The 52-week closing low was $197.38 on 27 April 2026, which shows how far the shares have moved in seven months.

Benzinga put AbbVie's market value at $509.83 billion on 6 November 2026. The next scheduled event is the ASH meeting from 12 December 2026. The fourth-quarter report, about 11 weeks out, is what settles the case.

Catalysts ahead

• 12 December 2026: ASH annual meeting opens in New Orleans (through 15 December 2026), with 22 epcoritamab abstracts and updated ISB 2001 Phase 1 data. Shows whether oncology pipeline assets can add growth to a franchise that rose only 0.8% in Q3 2026.
• ~26 December 2026 (est.): FDA decision on whether to accept the 27 October 2026 etentamig application in relapsed or refractory multiple myeloma. Acceptance starts a review clock for AbbVie's myeloma drug; a refusal would remove an oncology candidate from the near-term outlook.
• ~31 December 2026 (est.): FDA decision on Rinvoq for non-segmental vitiligo, which AbbVie expects in Q4 2026. Approval adds a new use for Rinvoq, one of the two drugs behind AbbVie's growth.
• ~31 December 2026 (est.): Antitrust clearance of the Nxera license; Nxera expects to book the $100 million upfront in its fourth quarter. If AbbVie books the payment in Q4, its 2026 adjusted EPS guidance would fall with no change in drug sales.
• 1 January 2027: 340B rebate model begins for Imbruvica, Linzess and Vraylar; Vraylar's Medicare-negotiated price takes effect. Shows how much the US pricing changes reduce 2027 net revenue; AbbVie has not yet put a number on the 340B effect.
• ~29 January 2027 (est.): Fourth-quarter 2026 report, with AbbVie's first 2027 guidance. Shows whether Skyrizi and Rinvoq growth and the 2027 earnings outlook justify a valuation above the stock's five-year average multiple.

What would change the view

A daily close below $270, under the 50-day moving average of $273.87 on 12 November 2026, which would show the post-report gain unwinding. 2027 guidance implying a sharp Skyrizi and Rinvoq slowdown, or a cut to 2026 adjusted EPS guidance for reasons other than deal charges, would also break the case.

The risks this note tracks, each with what would confirm it:

• Immunology growth slows as Skyrizi and Rinvoq get larger and rebate concessions rise. Confirmed by: 2027 guidance at the Q4 report implying Skyrizi or Rinvoq growth well below the 22–24% reported in Q3 2026.
• The shares trade well above their five-year average multiple, so earnings or guidance below expectations could pull them back. Confirmed by: Q4 2026 adjusted EPS at or below the $3.83–$3.87 guidance range, or 2027 EPS guidance below analysts' estimates at the Q4 report.
• Federal drug pricing, including 340B rebates and Medicare negotiation for Vraylar, reduces 2027 net prices. Confirmed by: AbbVie putting a 340B or Medicare revenue headwind into 2027 guidance that is larger than the low single-digit immunology rebate concession it has modeled.
• Deal spending keeps pushing earnings down, with the Nxera upfront next and Apogee diluting 2027. Confirmed by: further large licensing or acquisition charges in Q4 2026 or in 2027 guidance that push dilution beyond the about $0.46 AbbVie cited for Apogee.
• Aesthetics keeps shrinking on weak consumer demand. Confirmed by: AbbVie missing its $5 billion 2026 aesthetics guidance, or Juvederm sales still falling at a double-digit rate in Q4 2026.
• A rotation out of defensive sectors removes the support that lifted health care in October 2026. Confirmed by: health care lagging the S&P 500 as technology rebounds, with AbbVie falling alongside pharma peers without company news.

What it trades with

AbbVie trades with large US drugmakers and the health-care sector. A rotation out of defensive sectors and back into technology can pull the shares down without company news. Drug-pricing policy, including Medicare negotiation and the 340B changes, moves the whole group at once. Genmab shares in the economics of epcoritamab, and Nxera receives the IBD upfront payment. ASH data and the Nxera deal's antitrust clearance therefore move those partners along with AbbVie.